alpha-synuclein gene-silencing siRNAs (Alnylam)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug Namealpha-synuclein gene-silencing siRNAs (Alnylam)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionSynuclein alpha inhibitors

TargetsSynuclein alpha

Therapy Area/IndicationsParkinson Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAlnylam Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAlnylam Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A